Krishna Polu, Commit Biologics CEO
Danish biotech nabs Novo Holdings support in seed round for complement platform
Novo Holdings is pitching in to Commit Biologics’ seed funding for its research on “supercharging” antibodies to turn on the complement system, an approach that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.